Publications by authors named "Luke Ashcraft"

Claim this Profile
C
Correction to "Discovery of Nelutroctiv (CK-136), a Selective Cardiac Troponin Activator for the Treatment of Cardiovascular Diseases Associated with Reduced Cardiac Contractility".
Antonio Romero, Luke Ashcraft, Aroop Chandra, Vincent DiMassa, Peadar Cremin

J Med Chem· January 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pharmacokinetics, mass balance, tissue distribution, metabolism, and excretion of [C]aficamten following single oral dose administration to rats.
Mark P Grillo, Rajaa Sukhun, Mohammad Bashir, Luke Ashcraft, Bradley P Morgan

Xenobiotica· September 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
In vitro and in vivo preclinical pharmacokinetic characterization of aficamten, a small molecule cardiac myosin inhibitor.
Rajaa Sukhun, Peadar Cremin, Donghong Xu, Jeanelle Zamora, Jennifer Cheung, Luke Ashcraft

Xenobiotica· September 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Cardiac Troponin Activator Increases Cardiac Contractility in Rats.
Scott E Collibee, Antonio Romero, Alexander R Muci, Darren T Hwee, Chihyuan Chuang, Luke Ashcraft

J Med Chem· May 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Discovery of Nelutroctiv (CK-136), a Selective Cardiac Troponin Activator for the Treatment of Cardiovascular Diseases Associated with Reduced Cardiac Contractility.
Antonio Romero, Luke Ashcraft, Aroop Chandra, Vincent DiMassa, Peadar Cremin

J Med Chem· May 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Discovery of Aficamten (CK-274), a Next-Generation Cardiac Myosin Inhibitor for the Treatment of Hypertrophic Cardiomyopathy.
Chihyuan Chuang, Scott Collibee, Luke Ashcraft, Wenyue Wang, Mark Vander Wal

J Med Chem· October 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Discovery of Reldesemtiv, a Fast Skeletal Muscle Troponin Activator for the Treatment of Impaired Muscle Function.
Scott E Collibee, Gustave Bergnes, Chihyuan Chuang, Luke Ashcraft, Jeffrey Gardina

J Med Chem· October 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Discovery of the First Potent and Selective Inhibitor of Centromere-Associated Protein E: GSK923295.
Xiangping Qian, Andrew McDonald, Han-Jie Zhou, Nicholas D Adams, Cynthia A Parrish, Luke W Ashcraft

ACS Med Chem Lett· April 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis